It has also been recounted that the anti-inflammatory activity of 5 amino-salicylic acid (5-ASA), a first-line medication for the treatment of ulcerative colitis, requires the activation of epithelial PPAR-γ signaling, which makes it a potential target for therapeutic intervention in ulcerative colitis (Cevallos et al., 2021). Here, PPARG is linked to ulcerative colitis.